Close Menu

University College London

The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.

With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.